



The Digital Examiner
www.prostaaid.org

“Issue #309” November 2025



Guest Speaker November 19
A History of Cancer Clinical Trials in Canada:
How carcinoma of the prostate jostled for
trialists' attention.



Dr. Fedir Razumenko

Dr. Fedir Razumenko, a historian of medicine and science, has been a researcher at the Cumming School of Medicine, University of Calgary, since April 2019. That year his PhD thesis “Clinical Trials, Cancer, and the Emergence of Human Research Ethics in Canada, 1921-1980” received a University of Saskatchewan Doctoral Dissertation Award in the Fine Arts & Humanities.

One of his postdoctoral projects – “Cancer Clinical Trials in Canada and the Human Dignity Framework” explored the evolution of clinical investigations from a biomedical research paradigm to a patient-centered comprehensive investigation model.

Mark Your Calendar

DECEMBER 2025

S	M	T	W	T	F	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			

Our Annual Pathfinder Award Dinner
And Volunteer Appreciation Night
Is On Wednesday December 3rd
At The Grey Eagle Casino

Watch Your Inbox For Your Special Invite & Details

**Starting July 16th, our progressive 50/50 raffle
will run each month and the final draw will be
held at our 2025 Pathfinder Award event on
Wednesday December 3.
Pool Total To Date Is \$410**



This will be a 6 month consecutive sale of tickets at all of our General meetings. You must buy a ticket in person at one or all of these meetings. All tickets sold will be recorded so that if for any reason you are unable to attend the final draw, you will still be eligible. We will have an electronic paying option as well as cash. The ticket price is 1 for \$5 or 3 for \$10.

THERE WILL BE NO ONLINE SALES AT ALL ONLY IN PERSON SALES AND ALL SALES ARE FINAL

AGLC Licence# 733539



Warriors Lunch

Reminder to all of our Warriors that our next pizza lunch at Bella Roma Pizza in Lakeview is scheduled for **Tuesday November 4th starting at 11:30 am.**

Confirm your attendance and don't forget to bring \$20 to help cover the cost.

[RSVP jim.richardson@telus.net](mailto:jim.richardson@telus.net)

Bella Roma Pizza #17 6449 Crowchild Tr. SW.



***Great way to spend 3-5 hours
OR***

***How about donating 5 hours a month to us?
We're looking for new directors.
That's all we're asking for is 5 hours a month.
If interested let us know.
Email us at info@prostaid.org***



**All of our monthly General meetings are held on the third
Wednesday of every month**

Location for in person is:

CKE Community Centre (1015 73 Ave SW, Calgary, AB)

If you are unable to attend in person

Sign up [HERE](#) to join us online

Warriors & Wives Partners and Caregivers

**Wednesday, November 19th at CKE Community
Center**

**6:00 The warriors and wives, partners and
caregivers in their designated areas.**

**7:00 pm Everyone is welcome in the main hall for
social gathering time.**

7:30 pm General Meeting and feature presentation.



Donate Today

PROSTADID Calgary is a registered charity that relies on the generosity of its members, supporters and friends to achieve its goals. Tax receipts are issued for all amounts over \$20.00.

Your donations are used to support our monthly journal (the Digital Examiner), our free online video library, our website, our outreach programs and general awareness.

[Donate Today](#)

Connect With Us

Information
Phone 403 455 1916
info@prostaid.org
Brad Sterling
President
president@prostaid.org

[Connect With Us](#)

Support Groups

Jim Richardson
Warriors
jim.richardson@telus.net
Wives, Partners & Caregivers
Newly Diagnosed
info@prostaid.org

[Meeting Info Here](#)

Articles Of Interest



DRIVING CHANGE FOR MEN'S HEALTH

The MAN VAN® is Canada's first and only mobile men's health clinic offering FREE PSA (Prostate Specific Antigen) blood testing used for early detection of prostate cancer.

Now serving Edmonton & north for men 50 to 70 years of age


-No appointment necessary

-Testing ages 40 to 70

-Find the next community clinic near you

-15 minutes can save your life!

[MAN VAN UPCOMING CLINICS](#)



Apalutamide/ADT Displays Long-Term Efficacy in Recurrent Prostate Cancer

The addition of apalutamide (Erleada) to androgen deprivation therapy (ADT) reduced the risk of developing metastases and castration-resistant disease vs ADT alone among patients with biochemically recurrent prostate cancer

Trial info

October 2025
Cancernetwork

ADT



Drug combo cuts risk of death in advanced prostate cancer by 40%, clinical trial finds


"After initial treatment, some patients see their prostate cancer come back in an aggressive way and are at risk for their disease to spread quickly," said Stephen Freedland, MD, director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Cancer and co-principal investigator of the study.

"Hormone therapy, which is what we've been offering patients for 30 years, has not improved survival and neither has anything else. That makes these findings a real game changer."

Trial Info

October 2025
MedicalXpress

40% Risk



64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC

SAR-bisPSMA is a targeted copper theranostic that can be used for either imaging or therapy, depending on which copper isotope is paired with it. It was designed to connect 2 PSMA-targeting agents to the developer's sarcophagine technology that holds copper isotopes in a chelator; the sarcophagine technology prevents copper leakage into the body.

Study Overview

October 2025
Cancernetwork

64Cu-SAR




Future of BPH management lies in precision, personalization, and technology

The treatment landscape for benign prostatic hyperplasia (BPH) has undergone a rapid transformation over the past few years. With the advent of minimally invasive surgical therapies (MISTs) as well as artificial intelligence (AI), urologists are increasingly able to personalize treatment plans based on prostate anatomy and patient preferences.

AI holds particular promise in shaping how BPH is diagnosed, evaluated, and managed. Its applications extend across multiple domains, from improving diagnosis and treatment selection to guiding surgical planning and supporting patient education.

September 2025
Urology Times

BPH



Targeting enzymes to weaken cancer cells could supercharge prostate cancer treatment


"We've discovered a previously unknown mechanism that prostate cancer cells use to protect the androgen receptor, which is a key driver of the disease," says senior author, Professor Luke Selth.

"By targeting these enzymes, we can destabilize the AR and make tumors more vulnerable to existing therapies like enzalutamide."

[More Info Here](#)

October 2025
MedicalXpress

Targeting




Enzalutamide/Leuprolide Regimen Reduces Risk of Death in Prostate Cancer

Enzalutamide (Xtandi) plus leuprolide acetate exhibited a 40.3% lower risk of death compared with leuprolide acetate alone in patients with high-risk, biochemically recurrent prostate cancer, according to findings from the final overall analysis of the phase 3 EMBARK trial

[More Info](#)

October 2025
Cancernetwork

Reduce Risk



"PAM50 could now be used in recurrent prostate cancer to support shared decision making," according to study author Daniel Spratt, MD.

PAM50 Biomarker May Predict Apalutamide Efficacy in Prostate Cancer


The addition of apalutamide (Erleada) to secondary radiotherapy (SRT) produced clinically meaningful benefits among patients with recurrent prostate cancer and luminal B tumors, supporting PAM50 as a validated biomarker that may guide the use of hormone therapy.

We've been searching for decades for a way to determine which patients are most likely to respond to hormone therapy after prostatectomy. We now have a tool that lets us tailor treatment based on a tumor's biology and recommend hormone therapy only for those patients who we think can expect to see a benefit.

[More Info Here](#)

September 2025
Cancernetworkk

PAM50



High-speed whole-body SPECT tracks tumor evolution to optimize prostate cancer treatment


Lu-PSMA is a highly-targeted radionuclide treatment for metastatic castration-resistant prostate cancer (mCRPC). Conventional monitoring techniques during ^{177}Lu -PSMA therapy include analysis of the clinical condition and prostate-specific antigen (PSA) measurements.

PSMA PET/CT is also performed before and during treatment. ^{177}Lu SPECT imaging after each injection has shown potential for treatment monitoring, however, it often has long imaging times.

[Trial Info](#)

October 2025
MedicalXpress

Lu-PSMA



Canadian Prostate Cancer Guide

Resources, guides and tools to help caregivers, survivors and the recently diagnosed get clarity and more. Read empowering stories and share yours with us.

Bringing you the most up to date information in treatments, support, well-being, and more all in one place

We can help you in achieving the support you're looking for. On the Canadian Prostate Cancer Guide website you can look to find the most up to date information on prostate cancer in one place.

[Learn More Here](#)

Read about these articles below

- 1-PARP1-selective inhibitor
- 2-Metastasis-Directed Therapy
- 3-Bioengineering breathes new life into failed cancer treatment
- 4-Dietary pathways in prostate cancer: Insulin and inflammation
- 5-New targeted approach to shut down prostate cancer growth
- 6-Trial launches of neuromodulation therapy for erectile dysfunction
- 7-After cancer: Study explores caring-healing modalities for survivors
- 8-ClarityDX

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



Articles For Everyone



PARP1-selective inhibitor/ARPI combination is well tolerated in advanced prostate cancer

“The combination of androgen receptor pathway inhibitors and non-selective PARP inhibitors has shown clinically meaningful activity in patients with both metastatic castration-resistant prostate cancer^{2,3} and metastatic castration-sensitive prostate cancer.⁴ Saruparib is a new-generation PARP inhibitor that selectively inhibits and traps PARP1. In preclinical studies, saruparib shows improved targeted engagement, efficacy, and safety compared with non-selective PARP inhibitors”⁵

October 2025
Urology Times

PARP1




Metastasis-Directed Therapy Improves Outcomes in Various Solid Tumors

The phase 2 EXTEND study enrolled patients with 1 to 5 metastases from a wide range of solid tumors. The investigators randomly assigned patients to receive SOC with or without MDT. MDT involved radiation, radiofrequency ablation, or surgery. Outcomes included PFS, overall survival (OS), systemic immune response, and T-cell receptor expansion and contraction patterns.

Study Info

October 2025
Renal + Urology

Metastasis



Bioengineering breathes new life into failed cancer treatment

Many advanced cancers develop resistance to treatment and become highly aggressive, often leaving patients with limited treatment options. In some cancers, including lung, pancreatic and prostate tumors, a key driver of treatment resistance and metastasis is a protein called integrin $\alpha\beta3$, which is absent in normal tissues but enriched in aggressive tumors.

More Info

October 2025
MedicaXpress

Bioengineering




Dietary pathways in prostate cancer: Insulin and inflammation

For clinicians counseling patients Freedland acknowledged the challenge of distilling complex and heterogeneous dietary data into actionable advice during brief appointments. He recommends a practical approach: advise patients to avoid simple sugars, ultra-processed foods, and refined carbohydrates—dietary factors that spike insulin and inflammation. Instead, patients should focus on plant-based, whole-food dietary patterns or low-carbohydrate diets, both of which align with mechanisms shown to be protective.

More Info Here

September 2025
Urology Times

Dietary Pathway



Researchers find a new targeted approach to shut down prostate cancer growth

Prostate cancer relies on genetic "switches," called enhancers, that can turn on tumor-promoting genes. Researchers at the University of Michigan Health Rogel Cancer Center have discovered histone H2B N terminal acetylation (H2BNTac), an essential chemical mark of these enhancers. They further implicate two proteins, p300 and CBP, that add these marks, and along with the androgen receptor, turn on enhancers and promote prostate cancer growth.

[Read more here](#)

October 2025
MedicalXpress

Targeted




Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy

Participants in the study will begin activation of the device starting at 1 week post-op. The device includes an "implantable pulse generator containing a rechargeable battery and electronics responsible for generating the electrostimulation signal," according to Comphya. Activation of the device delivers electrical pulses to the cavernous nerves, potentially allowing patients to recover natural erectile function.

October 2025
Urology Times

ED



After cancer: Study explores caring-healing modalities for survivors

Growing research highlights resilience—the ability to recover from adversity—is a key factor in helping individuals manage distress and improve well-being. This underscores the urgent need for health care providers to adopt a whole-person approach that supports not just the body, but also the emotional and psychological needs of people with cancer.

October 2025
MedicalXpress

After Cancer

There's a lot riding on
your prostate health...
KNOW THE SCORE.

ClarityDX
prostate

ClarityDX Prostate uses clinical and blood-based biomarkers to determine a patient's risk of having clinically significant prostate cancer to help patients and their physicians make more informed healthcare decisions.

ClarityDX technology can be used to predict the risk of disease.

When it comes to a cancer diagnosis, Clarity means peace of mind. And when it comes to prostate cancer detection, it takes the right data to deliver that Clarity.

ClarityDX Prostate is a clinically proven decision support tool that uses a machine learning platform to calculate an accurate prostate cancer risk score from clinical data and multiple blood-based PSA test results (5-7).

If you have an elevated PSA, or a suspicion of prostate cancer, ClarityDX Prostate may be right for you. ClarityDX Prostate takes the fear and uncertainty out of prostate cancer screening.

ClarityDX

Thank you to our Sponsors and Community Partners



Disclaimer: The PROSTAID Calgary Society website & newsletter provides news and information about prostate issues and activities of the organization. While information is presented about prostate cancer and related issues, it is not intended as a substitute for professional medical advice, diagnosis, or treatment. PROSTAID Calgary Society recommends that you seek the advice of your physician or other qualified health professionals regarding questions you may have about any medical condition. Topics on

PROSTAID Calgary Society's website & newsletter are presented to inform you and we encourage you to seek professional medical advice before starting any treatment.

P.O. Box 72126
R.P.O. Glenmore Landing
Calgary, Alberta T2V 5H9



[Unsubscribe](#)